Attached files
file | filename |
---|---|
10-K - FORM 10-K - Immunoclin Corp | form10k.htm |
EX-31.1 - EXHIBIT 31.1 - Immunoclin Corp | exhibit311.htm |
EX-32.2 - EXHIBTI 32.2 - Immunoclin Corp | exhibit322.htm |
EX-31.2 - EXHIBIT 31.2 - Immunoclin Corp | exhibit312.htm |
EXCEL - IDEA: XBRL DOCUMENT - Immunoclin Corp | Financial_Report.xls |
Exhibit 32.1
Certification Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Annual Report of Pharma Investing News, Inc., (the Company) on Form 10-K for the year ended February 28, 2013, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Robert Kane, Chief Executive Officer of the Company certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
By: /s/ Robert Kane
Robert Kane
President and Chief Executive Officer
|